A vaccine against the most common and deadliest strain of avian flu, H5N1, has produced a strong immune response in mice and protected them from death following infection.
A vaccine against the most common and deadliest strain of avian flu, H5N1, has produced a strong immune response in mice and protected them from death following infection. The vaccine, engineered by researchers at the University of Pittsburgh’s Center for Vaccine Research (Pittsburgh, PA) and Novavax, Inc. (Rockville, MD), is now being tested in humans in an early-phase clinical trial.
Unlike other avian flu vaccines, which are partially developed from live viruses, this vaccine uses a virus-like particle, or VLP, that is recognized by the immune system as a real virus but lacks genetic information to reproduce, making it a potentially safer alternative for a human vaccine. Because of the evolving nature of H5N1, the vaccine was engineered to encode genes for three influenza viral proteins to offer enhanced protection against possible new strains of the virus.
Novavax release (PDF)
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.